Navigation Links
ViroPharma to Present at Three November Healthcare Conferences

EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting at several upcoming healthcare investment conferences.

Vincent Milano, president and chief executive officer of ViroPharma, will present at the Oppenheimer 20th Annual Healthcare Conference at 4:30 P.M. EST on Tuesday, November 3, 2009. The conference is being held at the Waldorf=Astoria in New York City.

Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Credit Suisse 2009 Healthcare Conference at 12:00 P.M. MST on Wednesday, November 11, 2009. The conference is being held at the Arizona Biltmore Hotel in Phoenix, AZ.

William Roberts, vice president, corporate communications will present at the Lazard Capital Markets 6th Annual Healthcare Conference at 2:45 P.M. EST on Wednesday, November 18, 2009. The conference is being held at the St. Regis Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Present at Four Additional Healthcare Conferences
2. ViroPharma to Present at Several Upcoming Healthcare Conferences
3. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
4. ViroPharma to Present at Two June Healthcare Conferences
5. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
6. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
7. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
8. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
10. ViroPharma to Present at Three November Healthcare Conferences
11. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
Post Your Comments:
(Date:11/30/2015)... MONTREAL , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... that it has joined the American Business Act on Climate ... economy that are standing with the Obama Administration to demonstrate ... for a strong outcome to the COP21 Paris ... . --> Sarnia, Canada . ...
(Date:11/30/2015)... 30, 2015  Culprits beware, a University at ... Jan Halámek, is taking crime scene fingerprint identification ...   -->   --> ... --> --> Halámek and ... a straightforward concept for identifying whether a culprit ...
(Date:11/30/2015)... Epigenetics Corp. ("Zenith" or the "Company") today announced that it ... Board of Directors to replace Dr. Peter Johann . ... as co-founder of Resverlogix, with expertise in the fields of ... --> Dr. Wong remarked, "I am very excited to ... expertise in epigenetics and the advanced stage of the R&D ...
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and ... The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately ... several North American tour dates. The Exhibition is based on Universal Pictures’ Jurassic ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... , October 29, 2015 ... authentication company focused on the growing mobile commerce ... announces that StackCommerce, a leading marketplace to discover ... the Wocket® smart wallet on StackSocial for this ... ("NXT-ID" or the "Company"), a biometric authentication company ...
(Date:10/27/2015)... Germany , October 27, 2015 ... SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically maps ... SMI,s Eye Tracking Glasses , so that they ... BeGaze. --> Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ...
Breaking Biology News(10 mins):